VISTAGEN THERAPEUTICS INC (VTGN)

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. The company is headquartered in South San Francisco, California and currently employs 33 full-time employees. The company went IPO on 2010-10-18. The firm focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.

Company Info

VISTAGEN THERAPEUTICS INC

343 Allerton Avenue

South San Francisco CALIFORNIA 94080

P: 16505773600

CEO: Shawn K. Singh

Employees: 33

Website: https://www.vistagen.com/